FDA合规计划7356.002C《放射性药品》修订版发布(2015-09-11)
Radioactive Drugs (7356.002C)
美国FDA于2015年9月11日发布合规计划7356.002C《放射性药品》修订版,更新了实施日期、完成日期、组织与程序变更及计划联系人。该计划要求各地区局对所有放射性药品检查适用本合规计划,检查报告须通过TurboEIR放射性药品专用模块电子提交;因违反21 CFR Part 210和211 CGMP而被列为OAI的常规商业生产检查,须经MARCS-CMS提交建议措施。
PDF 文字版;图形和原始排版请参阅官方 PDF。
第 1 页
FOOD AND DRUG ADMINISTRATION
COMPLIANCE PROGRAM PROGRAM 7356.002C
CHAPTER 56 - DRUG QUALITY ASSURANCE
SUBJECT: IMPLEMENTATION DATE
RADIOACTIVE DRUGS 09/11/2015
Revision Note: Program revised 09/11/2015 to update
COMPLETION DATE
implementation date, completion date,
organizational/procedural changes and program
contacts.
DATA REPORTING
PRODUCT CODES PRODUCT/ASSIGNMENT CODES
56002C DPI/RADIOACTIVE DRUGS
7356.002C
FIELD REPORTING REQUIREMENTS
(Excluding Winchester Engineering and Analytical Center [WEAC])
Establishment Inspection Reports (EIRs) are to be created and filed
electronically using the radioactive drug specific module in TurboEIR or
replacement system that is accessible to both ORA and CDER.
For inspections of routine commercial manufacturing classified as
Official Action Indicated (OAI) due to failure to comply with 21 CFR
Part 210 and 211 Current Good Manufacturing Practice (CGMP) as they
apply to radioactive drugs, submit advisory, administrative, or judicial
action recommendations via MARCS-CMS in accordance with the Regulatory
Procedures Manual (RPM).
Districts should immediately report significant issues according to
current FACTS, Panorama and CMS procedures. This includes promptly
filing and changing OAI notifications.
During an inspection, if you obtain information pertaining to inadequate
adverse drug experience (ADE) reporting, unapproved drug issues, or
post-approval reporting violations (application supplements, Field Alert
Reports (FARs), etc.), report in accordance with directions provided in
the applicable compliance programs and under separate captions in the
EIR. Data system information about these inspectional activities should
be reported under separate Program Assignment Codes (PACs).
Date of Issuance: 09/11//2015 COVER PAGE 1 of 2
)
第 2 页
FOOD AND DRUG ADMINISTRATION
COMPLIANCE PROGRAM PROGRAM 7356.002C
Expansion of coverage under these programs into a CGMP inspection should
be reported under this compliance program.
The Districts are requested to use this compliance program for all
radioactive drug inspections.
WINCHESTER ENGINEERING AND ANALYTICAL CENTER (WEAC) REPORTING
REQUIREMENTS
A. Forward all worksheets to Home District with copy to CDER/Office
of Product Quality (OPQ)/Office of Quality Surveillance(OQS).
B. Send by Electronic Mail System (EMS) results of the examination
of import samples to Home District.
COVER PAGE 2 of 2
Date of Issuance: 09/11//2015
)
第 3 页
FOOD AND DRUG ADMINISTRATION
COMPLIANCE PROGRAM PROGRAM 7356.002C
PART I - BACKGROUND
History
Radioactive drugs are regulated by the FDA to the same extent that FDA
regulates other drugs. With the exception of certain research uses of
radioactive drugs (as specified in 21 CFR 361.1), all
radiopharmaceuticals are considered to be new drugs and subject to the
applicable provisions of the Federal Food, Drug, and Cosmetic Act and
the drug regulations issued under Title 21 of the Code of Federal
Regulations.
Definition
The term "radioactive drug" is defined in 21 CFR 310.3 (n) as any
substance defined as a drug in the FD&C Act which exhibits spontaneous
disintegration of unstable nuclei with the emission of nuclear particles
or photons and includes any nonradioactive reagent kit or nuclide
generator which is intended to be used in the preparation of any such
substance but does not include drugs which contain only trace quantities
of naturally occurring radionuclides. The term "radioactive drug"
includes a "radioactive biological product" as defined in 21 CFR
600.3 (ee).
Exception for Research Use
On July 25, 1975, the FDA established a special provision in 21 CFR
361.1 for certain research uses of radioactive drugs provided:
• the research was approved by an FDA Radioactive Drug Research
Committee;
• the amount of active ingredient employed does not cause any
clinically detectable pharmacological effect in humans;
• the amount of radioactive material administered to each
subject is as low as is practicable; and,
• the radiation doses to the critical and target organs are
within certain specified limits.
Under these condition.~, radioactive drugs are generally recognized as
safe and effective when administered to human research subjects during
the course of a research project intended to obtain basic information
regarding the metabolism (including kinetics, distribution, and
localization) of a radioactively labeled drug or regarding human
physiology, pathophysiology, or biochemistry, but not intended for
immediate therapeutic, diagnostic, or similar purposes or to determine
the safety and effectiveness of the drug in humans for such purposes,
(i.e., to carry out a clinical trial).
Date of Issuance: 09/11//2015 PART I PAGE 1 of 2
第 4 页
FOOD AND DRUG ADMINISTRATION
COMPLIANCE PROGRAM PROGRAM 7356.002C
Certain basic research studies, e.g., studies to determine whether a drug
localizes in a particular organ or fluid space and to describe the kinetics
of that localization, may have eventual therapeutic or diagnostic
implications, but the initial studies are considered to be basic research
within the meaning of this provision. Compliance Program #7348.809A,
"Radioactive Drug Research Committees", covers the monitoring of radioactive
drugs for these research uses.
Date of Issuance: 09/11//2015 PART I PAGE 2 of 2
)
第 5 页
FOOD AND DRUG ADMINISTRATION
COMPLIANCE PROGRAM PROGRAM 7356.002C
PART II - IMPLEMENTATION
OBJECTIVES
*To provide guidance for conduction inspections of radioactive drug
manufacturers to determine compliance with the Food, Drug and Cosmetic Act
and the Current Good Manufacturing Practice Regulations (CGMP), Title
21, CFR Parts 210 and 211.
To initiate appropriate action against those manufacturers found to be out
of compliance.
To obtain information on key practices, to identify practices which need
correction or improvement, and to evaluate current good manufacturing
practices in the radiopharmaceutical industry.*
Pre-marketing aspects of ' radioactive drug products are covered under
Compliance Program #7346.832, "Pre-Approval Inspections." NDA methods
validations for radioactive drugs, as for other drugs, will be performed
by assignment.
PROGRAM MANAGEMENT INSTRUCTIONS
This program supplements CP #7356.002, "Drug Process Inspections," *and CP
7356.002A, "Sterile Drug Process Inspections" by providing specialized
instructions for conducting inspections of radioactive drug manufacturing
establishments.
Assignments for the collection of surveillance samples are issued under CP
#7356.008, "Drug Product Surveillance."
Coverage
The term "radioactive drugs" includes radioactive biological products. A
radioactive biological product is defined as a biological labeled or
intended to be labeled with a radionuclide.
Radioactive drugs may be administered orally, by injection, or
inhalation and may be either diagnostic or thereutic.
Date of Issuance: 09/11//2015 PART II PAGE 1 of 3
第 6 页
FOOD AND DRUG ADMINISTRATION
COMPLIANCE PROGRAM PROGRAM 7356.002C
1. A diagnostic radioactive drug functions in vivo as a radioactive
tracer which is distributed throughout the body, or localized in
particular organs or structures where the decay of the radioactive
element is detected externally. It may also be used in in vitro
clinical studies.
2. A therapeutic radioactive drug contains ' larger quantities of
radioactivity for destruction of diseased cells or tissues.
THIS COMPLIANCE PROGRAM DOES NOT COVER RADIOACTIVE MEDICAL DEVICES. A
radioactive medical device is a medical device as defined in Section 201(h)
of the FD&C Act that contains or utilizes radioactive materials.
Date of Issuance: 09/11//2015 PART II PAGE 2 of 3
第 7 页
FOOD AND DRUG ADMINISTRATION
COMPLIANCE PROGRAM PROGRAM 7356.002C
PART III - INSPECTIONAL
OPERATIONS
Districts will identify all manufacturers *(Attachment A deleted)* of
radioactive drugs and radioactive biologics, determine whether they are
registered under Section 510, and contact Division of Medical Imaging
Products for verification of the firm's NDA and IND filings.
An enforcement policy for "nuclear pharmacies" has been stated in 49 FR
24949 (June 18, 1984).
A guideline has been issued (May 1984) which aids in distinguishing
between those operations which are considered the practice of nuclear
pharmacy, and those operations which constitute the practice of drug
manufacturing.
Where an establishment has not registered as a drug manufacturer, but
manufacturing is suspected, attempt to inspect, and forward the EIR to
OPQ/ OQS for decision as to follow-up. The EIR should contain full
documentation explaining why the establishment considers itself a
pharmacy and why the district believes the establishment to be a drug
manufacturer.
Districts will inspect each radioactive drug manufacturer *a minimum of
once every two years on a surveillance basis* and will schedule
compliance inspections as needed. *See instructions under CP 7356.002 or
7356.002A concerning frequency of full vs. abbreviated inspections.* -
Districts and the Division of Drug Quality Evaluation will issue
assignments for collecting surveillance samples in coordination with
Winchester Engineering and Analytical Center (WEAC) under CP #7356.008,
"Drug Product Surveillance."
On assignment, the investigator team should review:
- All reference materials related to the type of products to be
covered by the assignment.
- Pertinent manufacturing, analytical, and labeling sections of the
IND or NDA, obtained if necessary from the OPQ/OQS.
- Compendial requirements for USP/NF products.
Date of Issuance: 09/11//2015 PART III PAGE 1 of 13
第 8 页
FOOD AND DRUG ADMINISTRATION
COMPLIANCE PROGRAM PROGRAM 7356.002C
- Current Good Manufacturing Practice Regulations, recognizing the
differences between standard drug manufacturing procedures and
the unique custom processing operations employed by the
radioactive drug and radiobiologic manufacturers.
- 40 FR 31297 - 31314 (July 25, 1975) (attached)
- 41 FR 7747 (Feb. 20, 1976) (attached)
- 41 FR 35171 (Aug. 20, 1976) (attached)
- Nuclear Pharmacy Guideline (May 1984)
Investigators selected by the districts to undertake assignments made under
this program will have completed the "FDA Advanced Training Course for Drug
Inspectors, Radiopharmaceuticals."
Districts should consider using an investigator/chemist team in making an
inspection of an establishment which has not been inspected previously. As
complex instrumentation and methodology may be involved, chemists with
education or training in nuclear science either from the district staff,
WEAC, DDC, or DORDP will be made available. The district may wish to use the
expertise of Regional Radiological Health personnel as members of the
investigating team.
Because of the nature of radioactive drugs, most producers manufacture small
batches based on anticipation of market needs, with production schedules
established accordingly. This is particularly true where the radioactive
nuclide has a short half-life and must be prepared, packaged, labeled,
shipped, and used in a relatively short period of time, sometimes in a
matter of hours.
All injectable radioactive drug products must comply with the normal
requirements of safety, sterility, freedom from pyrogens, acceptable pH, and
isotonicity. This is required by the United States Pharmacopeia with some
qualifiers regarding sterility testing. In addition, 21 CFR 211.165(a)
states, "where sterility and/or pyrogen testing are conducted on specific
batches of short-lived radiopharmaceuticals, such batches may be released
prior to completion of sterility or pyrogen testing, provided such testing
is completed as soon as possible."
In cases where it is necessary to permit the radioactivity for short-lived
nuclides to decay to a level allowing safe handling by laboratory personnel
performing the test or so that the radioactivity will not compromise the
test itself (e.g., injure the test animal), a delay in starting the test may
be allowed; however, testing of each batch must be accomplished as soon as
possible. Thus, investigators must realize that the production and quality
control aspects of the formulation of these products achieves an importance
which surpasses that employed in the marketing of the usual medicinal.
Date of Issuance: 09/11//2015 PART III PAGE 2 of 13
第 9 页
FOOD AND DRUG ADMINISTRATION
COMPLIANCE PROGRAM PROGRAM 7356.002C
If the district requests additional personnel, they should notify the
Division of Medical Products and Tobacco Program Operations (DMPTPO) with
copy to DORDP (HFD-150), WEAC (HFR-1300) or DPA, as appropriate, at least
three weeks in advance of the scheduled inspection so that a determination
can be made as to the individuals to participate in a given inspection.
Agreement State Programs
The Nuclear Regulatory Commission (NRC) has authority to enter into
agreements with State governments, with the State assuming regulatory
responsibility over the receipt, possession, use, disposal, storage, and
transfer of by-product source and specified quantities of special nuclear
material in that State. The State's program must be compatible with the NRC
program and the State must have the technical capability to protect public
health and safety. In addition to Agreement States, other states may
regulate the use of accelerator-produced or naturally-occurring radioactive
materials which are not controlled by NRC.
Agreement State radiation control personnel are frequently expert in the
detection of the improper use, manufacture, and safe-handling of radioactive
materials. These State Inspectors have the training and calibrated equipment
necessary to conduct radiation monitoring surveys, should it be deemed
necessary, and can readily recognize radiation safety hazards.
The Directory of Personnel Responsible for Radiological Health Programs
lists those professional personnel who administer the State and local
government agencies.
Districts may wish to contact State and local radiation control agencies
through their Regional Radiological Health Representative to obtain their
cooperation. This may include their participation in establishment
inspections as expert advisors on radiation safety, providing no information
normally considered confidential (i.e., IND*/NDA*) is to be covered.
All firms that manufacture and/or produce reactor-produced radiopharma-
ceuticals operate under a license issued by the NRC or a regulatory agency
of an Agreement State. Under the provisions of these licenses, each
manufacturer shall have an individual designated as a Radiation Safety
Officer (RSO) or radiation protection specialist. In addition, those areas
where radioactive drugs are produced and stored shall be posted with a
placard or sign bearing the radiation symbol and describing the radiation
and/or contamination levels, and the precautions to be taken while in those
areas (such as the wearing of protective clothing).
Date of Issuance: 09/11//2015 PART III PAGE 3 of 13
第 10 页
FOOD AND DRUG ADMINISTRATION
COMPLIANCE PROGRAM PROGRAM 7356.002C
*Format
Inspections of radiopharmaceutical drug manufacturers will be performed
under two compliance program guides, appropriate to the profile class of the
dosage form being inspected.
Non-sterile dosage form radiopharmaceuticals will be inspected utilizing the
instructions contained in Compliance Program #7356.002, Drug Process
Inspections, supplemented by the instructions peculiar to
radiopharmaceutical drug products contained in this Compliance Program.
Lyophilized and other sterile dosage form radiopharmaceuticals will be
inspected utilizing Compliance Program 7356.002A, *Sterile Drug Process
Inspections*, supplemented by the instructions specific to
radiopharmaceutical drug products contained in this Compliance Program.
Inspections of radiopharmaceutical manufacturing firms will be performed as
either Full Inspections or Abbreviated Inspections. The type of inspectional
option to be selected will be determined following the selection options
described in the Drug Process Compliance Program (7356-002) or *Sterile Drug
Process Inspections* Compliance Program (7356.002A), as relevant to the
product/profile class being covered. NOTE: Whether the Full or Abbreviated
Inspection option is selected, the information requested under this
(7356.002C) Radiopharmaceutical Compliance Program will be collected.*
INVESTIGATIONAL
Determine if establishment is registered under Section 510. Do not advise
that they must register if they consider themselves a pharmacy. See 41 ER
7747 (Feb. 20, 1976).
A. Radiological Safety
Investigator teams assigned to inspections of radioactive drug
manufacturers are expected to be familiar with radiation detection
equipment and safety precautions as follows:
Personnel dosimeters - supplied by the ORA Radiological Safety Officer
on a quarterly basis or as needed. Each badge is personally assigned and
worn only by the designated investigator or chemist. It is required to
be worn on the torso at all times during inspections or sampling
assignments involving procedures of radioactive drugs.
District Radiological Safety Representatives are responsible for
ordering and issuing dosimeters, and returning them to the ORA
Radiological Safety Officer for processing, if necessary. When not in
use, badges should be stored in a low radiation area away from sources
of heat and moisture.
Date of Issuance: 09/11//2015 PART III PAGE 4 of 13
第 11 页
FOOD AND DRUG ADMINISTRATION
COMPLIANCE PROGRAM PROGRAM 7356.002C
A self-reading dosimeter with a 0-200 mr range should also be carried
during these assignments. It should be read before, during, and after the
plant visit as an indicator of radiation exposure received for the period
involved. The serial number and initial and final readings of
self-reading dosimeters should be recorded for future reference.
Regional and District personnel now have available a personnel monitoring
device which activates with a noise and light signal when a pre-set dose
level is reached.
Handle these instruments with care as they may be discharged by shock if
dropped.
Required protective clothing such as smocks, bead and shoe covers, and
gloves are usually provided by the firm's Radiation Safety Officer (RSO).
The investigator should exercise particular care in areas where iodine or
technetium isotopes are being produced or processed to prevent an
internal dose by inhalation of the iodine or from skin absorption of the
technetium.
The firm's health physicist or RSO must accompany the investigator into
controlled areas where radionuclide-sand radioactive drug products are
processed, stored, or packaged. Avoid unnecessary handling of objects on
the premises and follow all safety procedures required by the firm.
After leaving the firm's controlled area, remove all protective clothing
by the "inside out" technique. Monitor yourself using the available
monitoring equipment after washing hands, face, and other exposed areas.
Leave protective clothing with the firm for disposal or laundering.
.1
Note: Each investigator is personally responsible for taking the
necessary precautions to reduce exposure to ionizing radiation to the
lowest possible level.
B. Raw Materials
Determine the adequacy of each firm's control procedures for handling raw
materials and components. These would include logging the receipt,
segregation, sampling, testing, and acceptance/release criteria, and
storage for:
1. Product containers and their components (vials, generators,
closures, syringes, needles, tubing, etc.).
2. Packaging materials.
3. Chemicals and other raw materials used in manufacturing, such as
gelatin, colloidal sulfur, saline solution, buffers, radiochemicals,
etc.
Date of Issuance: 09/11//2015 PART III PAGE 5 of 13
第 12 页
FOOD AND DRUG ADMINISTRATION
COMPLIANCE PROGRAM PROGRAM 7356.002C
4. Radionuclides.
C. Manufacturing Controls
Report:
1. Steps taken by the firm to prevent the absorption of radionuclides
on the walls of containers and preparation vessels. Document the
use of any coating materials and the firm's validation that
absorption does not occur and that delivery of the full dose is
assured.
2. Validated procedures utilized by the firm to prevent the carry over
of by-products from chemical reactions to the finished product.
3. The adequacy of pH controls during the processing of radioactive
drugs where pH is critical to the purity or activity of the
products, (e.g. iodine isotopes).
4. The accuracy of in-process equipment and the adequacy of controls
used to check whole bottle activity and/or container volume.
5. Controls used to maintain the identity of components used in
assembling kits, generators, etc.
6. Any failure of the manufacturer to establish acceptable limits on
theoretical and actual yields for small volume batches or
radioactive drugs manufactured on special order. Audit
representative batches manufactured before and during the
inspections.
7. Firm's procedures for monitoring the environment, personnel,
glassware, equipment, and various stages in processing for evidence
of contamination by radioactive materials.
8. Methods for retesting stock solutions used in manufacturing. Are
stock solutions checked for potency, impurities, and sterility
where required? Is reconciliation performed on the use of stock
solutions?
D. Manufacturing Radioactive Drugs and Radiobiologic Products Which
Meet Sterility Requirements (refer to CPG 7356.002A, Sterile Drug
Process Inspections)
*Report:*
1. Procedures used to insure that processing equipment, glassware,
final containers, and other components are free from chemical,
microbial, pyrogenic, and radioactive contamination.
Date of Issuance: 09/11//2015 PART III PAGE 6 of 13
第 13 页
FOOD AND DRUG ADMINISTRATION
COMPLIANCE PROGRAM PROGRAM 7356.002C
2. If re-use of stock solutions is encountered, the investigator should
report fully the precautions taken by the firm.
*Some portions deleted from this section due to duplication under the
Sterile Drug Process Compliance Program.
E. Generator Systems
The use of nuclide generators, such as the Mo 99m/Tt 99m generator, has
increased in recent years and they pose special problems. When
encountered during an inspection, report the following information:
1. Quality control procedures used in the assembly, testing and re-use
of the generator-system regarding the following areas:
- Assay
- Calibration
- Sterility
- Pyrogens
- pH
- Contaminants (radioactive and non-radioactive)
- Daily elution pattern
2. Any use of bacteriostats in the preparation of eluting solutions.
3. Instructions provided the user as to the assembly, operation and
maintenance of sterility.
4. Details of any training program designed for hospital personnel
authorized to use generator systems.
5. Determine the manufacturer of the generator and the source of the
radioactive materials within it.
F. Packaging and Labeling
1. Report procedures for storing, issuing and accounting for labeling
and insert materials. Give particular attention to small custom
batches.
2.
Determine the accuracy of the labeling statement for volume,
chemical
content, total activity per unit volume at data and time of
calibration. Report any difference between actual and theoretical
activity at date and time of calibration by the firm in comparison
to the labeled activity.
Date of Issuance: 09/11//2015 PART III PAGE 7 of 13
第 14 页
FOOD AND DRUG ADMINISTRATION
COMPLIANCE PROGRAM PROGRAM 7356.002C
3. A determination should be made that the kit label and the label of
each component of the kit bear the same expiration date which is
based on the component with the earliest expiration date. The
procedure used for assuring a single and valid expiration date for
multi-component kits should be reviewed.
4. Examples of labeling are to be submitted to CDER. CDER will review
storage precautions, directions for use, expiration date, and any
special limitation statements on product labeling for conformance
with compendial and/or NDA requirements.
5. Determine if in-process content uniformity checks are made on
capsules and if liquids are examined for fill of container and total
activity.
6. Report firm's procedures for identifying components (kits, syringes,
dilution bottles, etc.) packaged with the radioactive drug, or
shipped under separate order.
G. Analytical Controls
Report:
1. Any microbiological, chemical, and pyrogen tests performed on water
intended for parenteral preparations.
2. Tests to establish the potency and purity of reagents and materials
intended for tagging (e.g., vitamin B 12, colloidal sulfur, gelatin,
isotonic saline solution, etc.).
3. Any analysis of isotopes for radionuclide identification, and
purity, radiochemical identification, purity, and activity.
4. Sterility and/or pyrogen tests performed on presterilized
components, intermediates, and raw materials used in manufacturing.
5. Capsule preparations for content uniformity, chemical content, and
activity.
Date of Issuance: 09/11//2015 PART III PAGE 8 of 13
第 15 页
FOOD AND DRUG ADMINISTRATION
COMPLIANCE PROGRAM PROGRAM 7356.002C
6. Tests performed on finished radioactive drugs and biologicals as
follows:
- Chemical purity
- Radiochemical purity
- Radionuclidic identification and/or purity
- Total radioactivity (assay or radioassay)
- Sterility (USP requires that sterility tests be initiated
prior to shipment)
- pH and particulate matter
- Fill of container and packaging requirements
- Pyrogens (where required for injections)
- Toxicity
- Biodistribution
Note: Refer to NDA and/or compendial monograph for specific analytical
requirements.
7. Determine if analytical procedures follow NDA commitments and/or
compendial requirements.
8. The date and source of analytical standards.
9. Review the frequency and methods for standardizing the house
standards arid' stock solutions.
10. Current stability testing programs. Does the program data support
firm's expiration dating system?
11. During the first inspection, all instruments used in control
operations should be listed by name and model number. Any changes in
instrumentation should be noted on successive inspections.
12. Method and frequency of calibration of all quality control
instrumentation.
13. Determine the actual testing frequency for each test.
H. Complaints
1. Check complaint files for drug defects, drug administration
problems, adverse experience reports, and product rejections.
2. Report firm's response to complaints and the dispositions of any
returned goods.
Date of Issuance: 09/11//2015 PART III PAGE 9 of 13
第 16 页
FOOD AND DRUG ADMINISTRATION
COMPLIANCE PROGRAM PROGRAM 7356.002C
I. Products For Sampling
Identify products from firm's price list or catalog that should receive
analytical coverage based on inspectional findings, recalls, complaints,
etc. This list will be used by the OPQ/OQS in the selection of samples
for drug surveillance requests under CP #7356.008, "Drug Product
Surveillance."
When sampling is necessary to document violations, collect samples of
products from packaged stock ready for shipment. Select products with
half-lives sufficiently long so that time necessary for collecting
shipment and analysis is not a limiting factor.
J. Catalogs and Labeling
1. Obtain I copy of the firm's latest catalog or price list. Current
copies or revisions should be marked for referral to OPQ/OQS.
2. Obtain representative labeling of products inspected and attach as
exhibits.
SAMPLE COLLECTION
Requests to collect radioactive drug surveillance samples, both District-
initiated and Center-initiated will be issued under CP #7356.008, "Drug
Product Surveillance." Compliance samples will be collected at District
discretion or by direction of DDQE. Because the labs must schedule this
workload and remain within NRC radioactive material license possession
limits for the amount of radioactive material which may be on hand at any
time, the Districts will coordinate sampling with WEAC prior to collection.
Where necessary to document Good Manufacturing Practice Regulations (GMP)
deviations and other violations of the Act, official samples should be
collected in the following manner.
A. Collection
1. Collect documentary samples of raw materials, in-process
radioactive drugs, labeling, etc., to document GMP deviations
where physical samples are impractical.
2. Long-lived radionuclides may be collected from plant stocks or
from batches manufactured during the time of inspection and
after release by firm's quality control department.
Date of Issuance: 09/11//2015 PART III PAGE 10 of 13
第 17 页
FOOD AND DRUG ADMINISTRATION
COMPLIANCE PROGRAM PROGRAM 7356.002C
3. Many products, especially those of short-lived nuclides, are
manufactured on order only. In such cases it will be necessary to
obtain samples from products being packaged (filled) during a plant
visit. Such sampling must not prevent the manufacturer from meeting
customer orders. Arrange with the firm to determine the date of its
next regular production of the required products. If the timing is
satisfactory to the laboratory, arrange to have an additional amount
of a batch filled in order to provide for an FDA sample. Arrange with
the firm for the necessary transportation of the product so that
the sample will be delivered to the FDA laboratory in sufficient
time for analysis. The investigator should be present during
the production in order to observe as closely as possible the
labeling and filling operation of the product. Select required units
at random after the product has been filled and labeled.
Caution: Do not request the firm to manufacture or fill a batch for
the sole purpose of obtaining a sample.
4. If during an inspection, GMP deviations which are related to
potency, sterility, pyrogen problems or other contamination are
encountered, official samples should be collected. Contact
OPQ/OQS for assistance, if necessary.
B. Sample Size:
1. Collect a minimum of 20 capsules for Sodium iodide 1 131 Capsules,
Cyanocobalamin Co 57 Capsules, Cyanocobalamin Co 60 Capsules and any
other product where content uniformity is a compendial or NDA
requirement.
2. Collect the smallest commercial unit offered for sale in the median
dosage range when sampling oral preparations and sterile injections.
3. If plant conditions indicate the need for sterility, pyrogen, or
toxicity tests, contact the OPQ/OQS for sampling instructions and
sample size requirements.
C. Sampling Instructions
1. Do not handle the immediate container of any radioactive products.
2. Plant personnel should place the immediate container in a suitable
protective container in accordance with the establishment's
radioactive materials license and DOT shipping regulations.
Date of Issuance: 09/11//2015 PART III PAGE 11 of 13
第 18 页
FOOD AND DRUG ADMINISTRATION
COMPLIANCE PROGRAM PROGRAM 7356.002C
3. Officially seal the protective container before it is placed in
the final shipping container. It is not necessary to further
identify the protective container or to attach a FDA-525 to the
shipping container.
4. Obtain a copy of shipping records and product labeling for
attachment to your C/R.
5. Request the manufacturer to ship your sample via their normal
mode of transportation to the laboratory designated by
assignment:
U.S. Food & Drug Administration
Winchester Engineering and Analytical Center (HFR-NE490)
ATTN: Supervisory Chemist
109 Holton Street
Winchester, Massachusetts 01890
6. Report details concerning the product and shipment by telephone
to WEAC as follows:
a) C/R number and date sampled.
b) Name of product, activity, time of filling, expiration date
batch code, and number and size of unit(s) collected.
c) Name and address of manufacturer.
d) Reason for collection and analyses required.
e) Carrier and method of transportation, airbill number (when
appropriate).
f) Shipping date and expected date and time of arrival.
g) Pertinent information from shipping records.
7. Confirm by EMS the information provided by telephone to the
appropriate Radiological Safety Officer or to the RAL Supervisory
Chemist, WEAC (HER-NE490) for samples shipped to the Winchester
laboratory.
8. Prepare a Collection Report as soon as possible and send the
Sample Record Copy 4 (salmon) to the analyzing laboratory. Flag
the C/R "Radioactive Drug or Radioactive Biological Sample".
Forward a copy of the C/R to OPQ/OQS. Attach a copy of shipping
records and labeling to your original (white) C/R.
9. Under the Remarks section of your C/R report:
a) Potency (radioactivity) and the exact time and date the
Potency determination was made at the manufacturer or
repacker.
b) Any unusual or suspected practices which might affect the
product.
Date of Issuance: 09/11//2015 PART III PAGE 12 of 13
第 19 页
FOOD AND DRUG ADMINISTRATION
COMPLIANCE PROGRAM PROGRAM 7356.002C
IMPORTS
The Administration cannot, at present, readily determine the extent of
importation of radioactive drugs. In order to provide coverage, Districts
will alert Customs and other local officials to advise FDA of all imports
and will maintain surveillance by review of import entry forms, invoices,
etc. When shipments of sufficient size, frequency and suitable half-life are
encountered, consider collection of samples under the District-initiated
portion of the Drug Product Surveillance CP. Consult with the OPQ/OQS and
WEAC before attempting such sampling.
Inspection of foreign manufacturers will be coordinated by the Division of
Medical Products and Tobacco Inspections (DMPTI).
Considerations will be given to the district's ability to sample at port of
entry or at consignee's location (handling and shipping), nature of product,
size of lot, ability of laboratory to analyze, etc.
Release individual shipments being sent to physicians and hospitals after
determining that the drugs meet the requirements of 21 CFR 361.1 or are new
drugs covered by approved NDAs.
Date of Issuance: 09/11//2015 PART III PAGE 13 of 13
第 20 页
FOOD AND DRUG ADMINISTRATION
COMPLIANCE PROGRAM PROGRAM 7356.002C
PART IV - ANALYTICAL
Winchester Engineering and Analytical Center (WEAC) will analyze compliance
radioactive drug samples sent to them under this program. It will assist in
the inspection of these firms and collect samples. WEAC will validate
methodology of NDA's upon request of Division of Imaging Products (DIP).
WEAC will examine samples collected. Official and non-official preparations
will be tested by appropriate methodology which will include, but not be
limited to, the following basic analytical criteria:
- Radionuclide identity - demonstrating that the principal
radionuclide is the one it is declared to be.
- Radionuclide purity - identifying and quantifying radionuclide
contaminants.
- Radiochemical identity - demonstrating that the principal chemical
form of the radionuclide is the one it is declared to be.
- Radiochemical purity - showing the fraction of the principal
radionuclide which is in the specified chemical form.
- Radionuclide assay - measuring the radioactivity of the principal
radionuclide and comparing it 'with the label declaration.
- Non-radioactive chemical tests - establishing identity, purity, and
strength of non-radioactive components.
- Sterility or pyrogenicity - determinations, when necessary, will be
performed by WEAC.
- Biological distribution (Biological Efficacy), when necessary, will
be accomplished through sample preparation and animal work.
Date of Issuance: 09/11//2015 PART IV PAGE 1 of 1
第 21 页
FOOD AND DRUG ADMINISTRATION
COMPLIANCE PROGRAM PROGRAM 7356.002C
PART V - REGULATORY/ADMINISTRATIVE STRATEGY
In most cases, seizure or recall of small batches of short-lived radioactive
drug products will not be feasible because they are dispensed so quickly.
NAF and regulatory letters, injections and prosecution are other options.
Withdrawal of an NDA or a supplemental NDA is an additional option; however,
it has only been used on very rare occasions.
The Home District will consider all of the inspectional, analytical,
administrative, voluntary and regulatory follow-up options available when a
violative situation is encountered. The district will select the most
appropriate option or combination of options. Appropriate regulatory action
will be recommended to the OPQ/OQS.
*Refer to Part V of the Drug Process Inspections Compliance Program 7356.002
for general information on regulatory procedures.*
Date of Issuance: 09/11//2015 PART V PAGE 1 of 1
第 22 页
FOOD AND DRUG ADMINISTRATION
COMPLIANCE PROGRAM PROGRAM 7356.002C
PART VI - REFERENCES, ATTACHMENTS AND PROGRAM CONTACTS
REFERENCES
1. Radiation Safety Handbook for Ionizing and Non-Ionizing Radiation, DHEW
Publication (FDA) 77-8007 *(Current Revision)*
2. Safe Handling of Radioactive Materials, Handbook 92, U.S. Department of
Commerce, National Bureau of Standards, NCRP Report No. 2 (1964)
3. Remington's Pharmaceutical Sciences, *Current Edition*
4. Briner, W.H., "The Preparation of Radioactive Chemicals for Clinical
Use,* American J. Hospital Pharm., 20, 553-561 (1963)
5. USP/NF (Current Edition)
6. Radioactive Pharmaceuticals, USAEC. Division of Technical Information
Extension, Oak Ridge, TN, April, 1966, AEC Symposium Series No. 6
CONF-651111. ,
7. Cliggett, P.A. and Brown, J.M. "Assays of Radioactive Materials for Use
in Patients - A Five Year Study", Journal of Nuclear Medicine, 9,
236-240 (1967)
8. Radioisotope Directory, 2nd Edition (1971), Supplement to Dec. 1970
Nuclear
News, American Nuclear Society, Hillsdale, IL 60521
9. "Radiation Monitoring", AEC, Division of Technical Information
Extension, P.O. Box 62, Oak Ridge, TN 37830
10. AMA Drug Evaluation, Current Edition, American Medical Association,
Chicago, IL
11. Analytical Control of Radiopharmaceuticals, Proceedings of a Panel,
Vienna, 7-11 July (1969); International Atomic Energy Agency, Vienna,
(1970). Panel Proceedings Series. Unipub, Inc., P.O. Box 443, New York,
NY 10016
12. "Directory of Personnel Responsible for Radiological Health Programs",
Conference of Radiation Control Program Directors, Inc., 71 Fountain
Place, Frankfort, KY 40601, published annually.
13. "Radiopharmaceuticals" (1975) Society of Nuclear Medicine, New York
Date of Issuance: 09/11//2015 PART VI PAGE 1 of 3
)
第 23 页
FOOD
. AND DRUG ADMINISTRATION
COMPLIANCE PROGRAM PROGRAM 7 3 5 6 .002C ATTACHMENT A
14. Quality Control in Nuclear Medicine; Buck A. Rhodes (1977)
15. Federal Register of June 18, 1984 - 24949-50
*16. Inspection Technical Guide, "Radiation Protection Terminology,"
date 5/15/86, Number 44.*
*17. Regulatory Procedure Manual, Part 8*.
ATTACHMENTS:
A. Radioactive New Drugs and Radioactive Biologics - Termination of
Exceptions 40 FR 31297-31313 (July 25, 1975)
Radioactive Drugs, Including Biological Products - Notice to
Nuclear Pharmacies 40 FR 31314 (July 25, 1975)
B. Radioactive New Drugs and Radioactive Biologics; Extension of
Time for Continued Commercial Distribution
40 FR 7747 (Feb.20,1976)
C. Radioactive New Drugs and Radioactive Biologics; Extension of
Time for Continued Commercial Distribution 41 FR 35171 (August
20, 1976)
CONTACTS
A. ORA
Office of Operations (OO)/Office of Medical Products and Tobacco
Operations (OMPTO):
ORAHQDrugInspectionPOC@fda.hhs.gov
ORA/ORO/OR
S
Telephone: 301-796-6600
B. CDER
1. CGMP or any Quality-Related Policy Questions
For CGMP or any quality-related policy question, technical or
scientific questions or information needs, including questions about
this program, please send an email to the following address and it
will be handled as a top priority:
CDER-OPQ-Inquiries@fda.hhs.gov
Date of Issuance: 09/11//2015 PART VI PAGE 2 of 3
)
第 24 页
FOOD
. AND DRUG ADMINISTRATION
COMPLIANCE PROGRAM PROGRAM 7 3 5 6 .002C ATTACHMENT A
Enforcement-Related Guidance or Policy
For enforcement-related guidance or policy, including evidence
need and sufficiency, citations, and case
evaluation/recommendation advice, please send an email
to the following address and it will be handled as a top priority:
CDER OMQ Compliance Policy: CDEROMQCompliance@fda.hhs.gov
Labeling Requirements and Policies
Office of Unapproved Drugs and Labeling Compliance, see
intranet home page for contacts
[CDER | Office of Compliance | Office of Unapproved Drugs and
Labeling Compliance]
Registration and Drug Listing Requirements
CDER Office of Compliance, see “CDER: Who’s the Lead”
intranet page for contacts
[CDER | Office of Communications | CDER: Who’s the Lead]
2. To report shipments to laboratories and for problems with sample
collections and analyses, size, etc.:
a. Winchester Engineering and Analytical Center
ORA *(HFR-NE490)*
Telephone: FTS 839-8711 (area code 617)
b. CDER/OPQ/OQS
CDERSURVEILLANCE@fda.hhs.gov
3. For problems concerning radiation safety and protection:
Regional Radiological Health Representative,
or if not available:
Edmond Baratta, Radiation Safety Officer
Telephone 781-756-9742
Edmond.Baratta@fda.hhs.gov
Date of Issuance: 09/11//2015 PART VI PAGE 3 of 3
)
第 25 页
FOOD
. AND DRUG ADMINISTRATION
COMPLIANCE PROGRAM PROGRAM 7 3 5 6 .002C ATTACHMENT A
PART VII - CENTER RESPONSIBILITIES
The OPQ/OQS will review all Establishment Inspection Reports forwarded by the
Districts. Districts will keep the OPQ/OQS advised of their plans for surveillance
and compliance sampling. This Division will evaluate
all laboratory findings.
CDER will review storage precautions, directions for use, expiration date, and
any special limitation statements for product labeling for conformance with
compendial and/or NDA requirements.
Program
Evaluation_
The OPQ/OQS will periodically evaluate this activity. Evaluations will be made
generally available.
Date of Issuance: 09/11//2015 PART VII PAGE 1 of 1
)
第 26 页
FOOD
. AND DRUG ADMINISTRATION
COMPLIANCE PROGRAM PROGRAM 7 3 5 6 .002C ATTACHMENT A
ED: Attachment A is a copy of the Federal register: not included in scanning.
FRIDAY, JULY 25, 1975
WASHINGTON, D.C.
Volume 40 Number 144
PART II
DEPARTMENT OF
HEALTH,
EDUCATION, AND
WELFARE
Food and Drug Administration
RADIOACTIVE DRUGS
AND RADIOACTIVE
BIOLOGICAL PRODUCTS
Date of Issuance: 09/11//2015 PAGE 1 of 1
)
来源:FDA 官方药品与生物制品信息 · fda.gov